Provided by Tiger Fintech (Singapore) Pte. Ltd.

Day One Biopharmaceuticals Inc.

7.14
+0.30004.39%
Pre-market: 7.01-0.1300-1.82%04:27 EDT
Volume:1.94M
Turnover:14.02M
Market Cap:723.67M
PE:-6.97
High:7.55
Open:6.75
Low:6.73
Close:6.84
Loading ...

Day One Biopharmaceuticals Reports 2024 Financial Results

TIPRANKS
·
26 Feb

Day One Biopharmaceutical Q4 GAAP EPS $(0.69) Misses $(0.36) Estimate, Sales $29.21M Beat $27.79M Estimate

Benzinga
·
26 Feb

Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

GlobeNewswire
·
26 Feb

Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates

Zacks
·
21 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
21 Feb

Does Day One Biopharmaceuticals (DAWN) Have the Potential to Rally 193.16% as Wall Street Analysts Expect?

Zacks
·
13 Feb

New Strong Buy Stocks for February 13th

Zacks
·
13 Feb

Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025

GlobeNewswire
·
11 Feb

Analysts Are Bullish on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), Health Catalyst (HCAT)

TIPRANKS
·
11 Feb

Tara Bancroft’s Buy Rating: Ojemda’s Promising Growth and Strong Financial Prospects

TIPRANKS
·
29 Jan

Why Is Andreas Halvorsen Bullish On Day One Biopharmaceuticals, Inc. (DAWN) Now?

Insider Monkey
·
23 Jan

Strategic Positioning and Growth Potential of Day One Biopharmaceuticals: A Buy Rating Driven by Ojemda’s Market Penetration

TIPRANKS
·
16 Jan

Day One Biopharm Price Target Maintained With a $33.00/Share by Needham

Dow Jones
·
14 Jan

Optimistic Outlook for Day One Biopharmaceuticals: Strong Sales Performance and Promising Pipeline Support Buy Rating

TIPRANKS
·
13 Jan

Press Release: Day One Reports Preliminary 2024 OJEMDA(TM) Net Product Revenue and Highlights 2025 Corporate Priorities

Dow Jones
·
13 Jan

Day One Biopharm Is Maintained at Buy by B of A Securities

Dow Jones
·
08 Jan

BofA Securities Adjusts Price Target on Day One Biopharmaceuticals to $25 From $28, Maintains Buy Rating

MT Newswires Live
·
07 Jan

3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025

Zacks
·
27 Dec 2024

High Growth Tech Stocks to Watch in December 2024

Simply Wall St.
·
24 Dec 2024

Day One Biopharmaceuticals (DAWN) Posts Stellar Q3 but with Extreme Concentration Risk

TIPRANKS
·
17 Dec 2024